PERSEUS Workhorse (WH) | PERSEUS Small Vessel (SV)

Key Inclusion Criteria
- Subjects ≥18 years old
- Documented stable or unstable angina pectoris, or documented silent ischemia
- Left ventricular ejection fraction ≥30%
- De novo target lesion in a native coronary artery with angiographic diameter stenosis ≥50%, coverable by a single study stent

Reference Vessel Diameter
≥2.75mm to ≤4.0mm
≥2.25mm to <2.75 mm

Cumulative Target Lesion Length
≤28mm
≤20mm

Dual Antiplatelet Therapy
- Mandatory loading dose of ≥300 mg p.o. Clopidogrel (600 mg recommended) or 500 mg p.o ticlopidine
- Mandated compliance with current ACC/AHA/SCAI Guidelines for PCI for patients treated with drug-eluting stents
- Aspirin (ASA) mandated concomitantly with clopidogrel or ticlopidine; recommended indefinitely

Enrollment
N=1264
N=224

Randomization
3:1 Single Arm

Clinical Follow-Up
30 days, 9 months, 12 months, 18 months, 2 years, 3 years, 4 years, 5 years

Angiographic Follow-Up
9 Months
330-Subject Randomized Angiographic Subset
9 Months
All Subjects

Primary Endpoint
12-Month Target Lesion Failure
9-Month In-Stent Late Loss

Secondary Endpoint
9-Month In-Segment % Diameter Stenosis
12-Month Target Lesion Failure